98 related articles for article (PubMed ID: 29061645)
21. SCORE: Shared care of Colorectal cancer survivors: protocol for a randomised controlled trial.
Jefford M; Emery J; Grunfeld E; Martin A; Rodger P; Murray AM; De Abreu Lourenco R; Heriot A; Phipps-Nelson J; Guccione L; King D; Lisy K; Tebbutt N; Burgess A; Faragher I; Woods R; Schofield P
Trials; 2017 Oct; 18(1):506. PubMed ID: 29084595
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
[TBL] [Abstract][Full Text] [Related]
23. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM
Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883
[TBL] [Abstract][Full Text] [Related]
24. Prognostic gene expression signature for high-grade serous ovarian cancer.
Millstein J; Budden T; Goode EL; Anglesio MS; Talhouk A; Intermaggio MP; Leong HS; Chen S; Elatre W; Gilks B; Nazeran T; Volchek M; Bentley RC; Wang C; Chiu DS; Kommoss S; Leung SCY; Senz J; Lum A; Chow V; Sudderuddin H; Mackenzie R; George J; ; Fereday S; Hendley J; Traficante N; Steed H; Koziak JM; Köbel M; McNeish IA; Goranova T; Ennis D; Macintyre G; Silva De Silva D; Ramón Y Cajal T; García-Donas J; Hernando Polo S; Rodriguez GC; Cushing-Haugen KL; Harris HR; Greene CS; Zelaya RA; Behrens S; Fortner RT; Sinn P; Herpel E; Lester J; Lubiński J; Oszurek O; Tołoczko A; Cybulski C; Menkiszak J; Pearce CL; Pike MC; Tseng C; Alsop J; Rhenius V; Song H; Jimenez-Linan M; Piskorz AM; Gentry-Maharaj A; Karpinskyj C; Widschwendter M; Singh N; Kennedy CJ; Sharma R; Harnett PR; Gao B; Johnatty SE; Sayer R; Boros J; Winham SJ; Keeney GL; Kaufmann SH; Larson MC; Luk H; Hernandez BY; Thompson PJ; Wilkens LR; Carney ME; Trabert B; Lissowska J; Brinton L; Sherman ME; Bodelon C; Hinsley S; Lewsley LA; Glasspool R; Banerjee SN; Stronach EA; Haluska P; Ray-Coquard I; Mahner S; Winterhoff B; Slamon D; Levine DA; Kelemen LE; Benitez J; Chang-Claude J; Gronwald J; Wu AH; Menon U; Goodman MT; Schildkraut JM; Wentzensen N; Brown R; Berchuck A; Chenevix-Trench G; deFazio A; Gayther SA; García MJ; Henderson MJ; Rossing MA; Beeghly-Fadiel A; Fasching PA; Orsulic S; Karlan BY; Konecny GE; Huntsman DG; Bowtell DD; Brenton JD; Doherty JA; Pharoah PDP; Ramus SJ
Ann Oncol; 2020 Sep; 31(9):1240-1250. PubMed ID: 32473302
[TBL] [Abstract][Full Text] [Related]
25. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment.
Wheeler DA; Takebe N; Hinoue T; Hoadley KA; Cardenas MF; Hamilton AM; Laird PW; Wang L; Johnson A; Dewal N; Miller V; Piñeyro D; Castro de Moura M; Esteller M; Shen H; Zenklusen JC; Tarnuzzer R; McShane LM; Tricoli JV; Williams PM; Lubensky I; O'Sullivan-Coyne G; Kohn EC; Little RF; White J; Malik S; Harris L; Weil C; Chen AP; Karlovich C; Rodgers B; Shankar L; Jacobs P; Nolan T; Hu J; Muzny DM; Doddapaneni H; Korchina V; Gastier-Foster J; Bowen J; Leraas K; Edmondson EF; Doroshow JH; Conley BA; Ivy SP; Staudt LM
Cancer Cell; 2021 Jan; 39(1):38-53.e7. PubMed ID: 33217343
[TBL] [Abstract][Full Text] [Related]
26. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Burdett NL; Willis MO; Alsop K; Hunt AL; Pandey A; Hamilton PT; Abulez T; Liu X; Hoang T; Craig S; Fereday S; Hendley J; Garsed DW; Milne K; Kalaria S; Marshall A; Hood BL; Wilson KN; Conrads KA; Pishas KI; Ananda S; Scott CL; Antill Y; McNally O; Mileshkin L; Hamilton A; Au-Yeung G; Devereux L; Thorne H; Bild A; Bateman NW; Maxwell GL; Chang JT; Conrads TP; Nelson BH; Bowtell DDL; Christie EL
Nat Genet; 2023 Mar; 55(3):437-450. PubMed ID: 36849657
[TBL] [Abstract][Full Text] [Related]
27. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Yoon WH; DeFazio A; Kasherman L
Cancer Drug Resist; 2023; 6(2):358-377. PubMed ID: 37457131
[TBL] [Abstract][Full Text] [Related]
29. A medley of resistance in ovarian cancers.
Hernando B; Macintyre G
Nat Genet; 2023 Mar; 55(3):361-362. PubMed ID: 36849656
[No Abstract] [Full Text] [Related]
30. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
31. The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models.
Ho GY; Vandenberg CJ; Lim R; Christie EL; Garsed DW; Lieschke E; Nesic K; Kondrashova O; Ratnayake G; Radke M; Penington JS; Carmagnac A; Heong V; Kyran EL; Zhang F; Traficante N; ; Huang R; Dobrovic A; Swisher EM; McNally O; Kee D; Wakefield MJ; Papenfuss AT; Bowtell DDL; Barker HE; Scott CL
Ther Adv Med Oncol; 2023; 15():17588359231208674. PubMed ID: 38028140
[TBL] [Abstract][Full Text] [Related]
32. Concurrent RB1 loss and
Saner FAM; Takahashi K; Budden T; Pandey A; Ariyaratne D; Zwimpfer TA; Meagher NS; Fereday S; Twomey L; Pishas KI; Hoang T; Bolithon A; Traficante N; Alsop K; Christie EL; Kang EY; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Alsop J; Beckmann MW; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; El-Bahrawy MA; Elishaev E; Erber R; Gayther SA; Gentry-Maharaj A; Blake Gilks C; Harnett PR; Harris HR; Hartmann A; Hein A; Hendley J; ; Hernandez BY; Jakubowska A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Kluz T; Koziak JM; Kristjansdottir B; Le ND; Lener M; Lester J; Lubiński J; Mateoiu C; Orsulic S; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Rinda Soong T; Steed H; Sukumvanich P; Talhouk A; Taylor SE; Vierkant RA; Wang C; Widschwendter M; Wilkens LR; Winham SJ; Anglesio MS; Berchuck A; Brenton JD; Campbell I; Cook LS; Doherty JA; Fasching PA; Fortner RT; Goodman MT; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Menon U; Modugno F; Pharoah PDP; Schildkraut JM; Sundfeldt K; Swerdlow AJ; Goode EL; DeFazio A; Köbel M; Ramus SJ; Bowtell DDL; Garsed DW
medRxiv; 2023 Nov; ():. PubMed ID: 37986741
[TBL] [Abstract][Full Text] [Related]
33. Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma.
Benada J; Bulanova D; Azzoni V; Petrosius V; Ghazanfar S; Wennerberg K; Sørensen CS
NAR Cancer; 2023 Sep; 5(3):zcad029. PubMed ID: 37325550
[TBL] [Abstract][Full Text] [Related]
34. A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer.
Mo J; Ruan S; Yang B; Jin Y; Liu K; Luo X; Jiang H
J Zhejiang Univ Sci B; 2023 Jan; 24(1):64-77. PubMed ID: 36632751
[TBL] [Abstract][Full Text] [Related]
35. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract][Full Text] [Related]
36. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Garsed DW; Pandey A; Fereday S; Kennedy CJ; Takahashi K; Alsop K; Hamilton PT; Hendley J; Chiew YE; Traficante N; Provan P; Ariyaratne D; Au-Yeung G; Bateman NW; Bowes L; Brand A; Christie EL; Cunningham JM; Friedlander M; Grout B; Harnett P; Hung J; McCauley B; McNally O; Piskorz AM; Saner FAM; Vierkant RA; Wang C; Winham SJ; Pharoah PDP; Brenton JD; Conrads TP; Maxwell GL; Ramus SJ; Pearce CL; Pike MC; Nelson BH; Goode EL; DeFazio A; Bowtell DDL
Nat Genet; 2022 Dec; 54(12):1853-1864. PubMed ID: 36456881
[TBL] [Abstract][Full Text] [Related]
37. Molecular Management of High-Grade Serous Ovarian Carcinoma.
Punzón-Jiménez P; Lago V; Domingo S; Simón C; Mas A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430255
[TBL] [Abstract][Full Text] [Related]
38. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley DM; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; Swisher EM; Maloney L; Goble S; Lin KK; Kwan T; Ledermann JA; Coleman RL
Gynecol Oncol; 2022 Dec; 167(3):404-413. PubMed ID: 36273926
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
